Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
Open accessThe DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations to PKD1 or PKD2, triggering progressive cystogenesis and typically leading to end-stage renal disease in midlife. The phenotypic spectrum, however, ranges from in utero onset to adequate renal function at old age. Recent patient data suggest that the disease is dosage dependent, where incompletely penetrant alleles influence disease severity. Here, we have developed a knockin mouse model matching a likely disease variant, PKD1 p.R3277C (RC), and have proved that its functionally hypomorphic nature modifies the ADPKD phenotype. While Pkd1+/null mice are normal, Pkd1RC/null mice have rapidly progressive disease, and Pkd1RC/RC animals develop gradual cystogenesis. These models effectively mimic the pathophysiological features of in utero-onset and typical ADPKD, respectively, correlating the level of functional Pkd1 product with disease severity, highlighting the dosage dependence of cystogenesis. Additionally, molecular analyses identified p.R3277C as a temperature-sensitive folding/trafficking mutant, and length defects in collecting duct primary cilia, the organelle central to PKD pathogenesis, were clearly detected for the first time to our knowledge in PKD1. Altogether, this study highlights the role that in trans variants at the disease locus can play in phenotypic modification of dominant diseases and provides a truly orthologous PKD1 model, optimal for therapeutic testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies revealed that mutations in Prksch or Sec63 greatly reduce the expression, stability and proper trafficking of polycystin-1 (PC1), leading to cyst formation in a dose-dependent manner [426,427].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [427]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and proteomic profiling of exosomes in human urine
Pisitkun, T., Shen, R.-F., & Knepper, M. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403453101 · Cited by 2,174 · cited 2×
“21, 22).”
Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells
Nauli, S. M., Alenghat, F. J., Luo, Y., Williams, E., Vassilev, P., Li, X., Elia, A. E. H., Lu, W., Brown, E. M., Quinn, S. J., et al. (2003) · Nature Genetics · doi:10.1038/ng1076 · Cited by 2,057 · cited 2×
“However, in PKD1, the majority of studies have not detected cilia length defects, but the data are not conclusive, as these studies were largely conducted by light microscopy using cultured cells (14, 15, 80, 81).”
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Self-citationPKD2 , a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein
Mochizuki, T., Wu, G., Hayashi, T., Xenophontos, S. L., Veldhuisen, B., Saris, J. J., Reynolds, D. M., Cai, Y., Gabow, P. A., Pierides, A., et al. (1996) · Science · doi:10.1126/science.272.5266.1339 · Cited by 1,406 · cited 1×
“3) and PKD2 (4q21), mutated in approximately 85% and 15% of cases, respectively (3–5).”
Hildebrandt, F., Benzing, T., & Katsanis, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010172 · Cited by 1,331
A Highly Efficient Recombineering-Based Method for Generating Conditional Knockout Mutations
Liu, P., Jenkins, N. A., & Copeland, N. G. (2003) · Genome Research · doi:10.1101/gr.749203 · Cited by 1,013 · cited 1×
“A β -lactamase expression cassette flanked with a 3 ′ Sal I site was recom-bineered into IVS30, using the DY380 E. coli strain (63).”
Yoder, B. K., Hou, X., & Guay-Woodford, L. M. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000029587.47950.25 · Cited by 935
Hughes, J., Ward, C. J., Peral, B., Aspinwall, R., Clark, K., San Millán, J. L., Gamble, V., & Harris, P. C. (1995) · Nature Genetics · doi:10.1038/ng0695-151 · Cited by 910 · cited 1×
“82, 83).”
Self-citationDise, T. E. P. K. (1994) · Cell · doi:10.1016/0092-8674(94)90137-6 · Cited by 903
Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents
Hanaoka, K., Qian, F., Boletta, A., Bhunia, A. K., Piontek, K., Tsiokas, L., Sukhatme, V. P., Guggino, W. B., & Germino, G. G. (2000) · Nature · doi:10.1038/35050128 · Cited by 818 · cited 1×
“One possibility is that the PC complex acts as a mechanosensor, signaling via a Ca 2+ influx through PC-2, a TRP channel, after fluid flow detection by PC-1 (14, 16, 20).”
Research works printed but not linked: 1
- Dalgaard, 1957, Acta Med Scand Suppl., 328, 1
Cited by
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Self-citationAutosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Type of PKD1 Mutation Influences Renal Outcome in ADPKD
Cornec-Le Gall, E., Audrézet, M.-P., Chen, J.-M., Hourmant, M., Morin, M.-P., Perrichot, R., Charasse, C., Whebe, B., Renaudineau, E., Jousset, P., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070650 · Cited by 530
Porath, B., Gainullin, V. G., Cornec-Le Gall, E., Dillinger, E. K., Heyer, C. M., Hopp, K., Edwards, M. E., Madsen, C. D., Mauritz, S. R., Banks, C. J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.05.004 · Cited by 475
Self-citationGenetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Cornec-Le Gall, E., Torres, V. E., & Harris, P. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050483 · Cited by 406
Self-citationGenetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease
Harris, P. C., & Torres, V. E. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72272 · Cited by 338
“A hypothesis is now becoming accepted in which cysts develop below a specific PC threshold, with the dosage of functional PC associated with disease severity (36, 43, 44).”
InfluentialSelf-citationMonoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease
Cornec-Le Gall, E., Olson, R. J., Besse, W., Heyer, C. M., Gainullin, V. G., Smith, J. M., Audrézet, M.-P., Hopp, K., Porath, B., Shi, B., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.03.013 · Cited by 312
“PC1 is cleaved at a G protein-coupled receptor proteolytic site (GPS), and the level of mature, cleaved glycoforms of PC1 is associated with disease severity.(13,14) GANAB encodes the a-subunit of glucosidase II (the ADPLD gene, PRKCSH [MIM: 177060], encodes the b subunit), a resident enzyme of the endoplasmic reticul…”
Self-citationStrategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
Torres, V. E., & Harris, P. C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040398 · Cited by 289
Self-citationStructure of the human PKD1-PKD2 complex
Su, Q., Hu, F., Ge, X., Lei, J., Yu, S., Wang, T., Zhou, Q., Mei, C., & Shi, Y. (2018) · Science · doi:10.1126/science.aat9819 · Cited by 284
“Mutation R3277C in the NTMD has been suggested to affect the folding, glycosylation, and trafficking of PKD1 (46).”
BackgroundHajarnis, S., Lakhia, R., Yheskel, M., Williams, D., Sorourian, M., Liu, X., Aboudehen, K., Zhang, S., Kersjes, K., Galasso, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14395 · Cited by 211
Self-citationHeyer, C. M., Sundsbak, J. L., Abebe, K. Z., Chapman, A. B., Torres, V. E., Grantham, J. J., Bae, K. T., Schrier, R. W., Perrone, R. D., Braun, W. E., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050583 · Cited by 190
Self-citationFood Restriction Ameliorates the Development of Polycystic Kidney Disease
Warner, G., Hein, K. Z., Nin, V., Edwards, M., Chini, C. C. S., Hopp, K., Harris, P. C., Torres, V. E., & Chini, E. N. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015020132 · Cited by 187
Self-citationmiR-17∼92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease
Patel, V., Williams, D., Hajarnis, S., Hunter, R., Pontoglio, M., Somlo, S., & Igarashi, P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301693110 · Cited by 181
“The renal phenotype of miR-17∼92 OEmice is similar to mice that are homozygous for a hypomorphic allele of Pkd1 (30).”
BackgroundMetabolism and mitochondria in polycystic kidney disease research and therapy
Padovano, V., Podrini, C., Boletta, A., & Caplan, M. J. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0051-1 · Cited by 181
Devuyst, O., Ahn, C., Barten, T. R. M., Brosnahan, G., Cadnapaphornchai, M. A., Chapman, A. B., Gall, É. C.-L., Drenth, J. P. H., Gansevoort, R. T., Harris, P. C., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.07.009 · Cited by 177
Self-citationA polycystin-centric view of cyst formation and disease: the polycystins revisited
Ong, A. C. M., & Harris, P. C. (2015) · Kidney International · doi:10.1038/ki.2015.207 · Cited by 176
“In mice, slowly progressive disease occurs if the level of functional PC1 is ~40%, but rapidly progressive disease occurs with ~20% functional PC1, highlighting the influence of dosage 36 (Figure 1).”
InfluentialSelf-citationSenum, S. R., Li, Y. (. M., Benson, K. A., Joli, G., Olinger, E., Lavu, S., Madsen, C. D., Gregory, A. V., Neatu, R., Kline, T. L., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.016 · Cited by 174
Self-citationInsights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies
Lanktree, M. B., Haghighi, A., di Bari, I., Song, X., & Pei, Y. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02320220 · Cited by 166
“However, complete inactivation of both copies of PKD1 or PKD2 is not necessary for cyst initiation as studies of hypomorphic mutant mouse models showed cyst development with low levels (approximately 20%) of polycystin-1 (13,14).”
BackgroundRefining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease
Hwang, Y.-H., Conklin, J., Chan, W., Roslin, N. M., Liu, J., He, N., Wang, K., Sundsbak, J. L., Heyer, C. M., Haider, M., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060648 · Cited by 160
Self-citationAltered trafficking and stability of polycystins underlie polycystic kidney disease
Cai, Y., Fedeles, S. V., Dong, K., Anyatonwu, G., Onoe, T., Mitobe, M., Gao, J.-D., Okuhara, D., Tian, X., Gallagher, A.-R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67273 · Cited by 158
“Functional defects resulting from missense mutations thought to be patho genic in ADPKD include loss of GPS cleavage (73) and changes in protein folding and trafficking (47) in PC1 and loss of channel activity in PC2 (17).”
Vasopressin and disruption of calcium signalling in polycystic kidney disease
Chebib, F. T., Sussman, C. R., Wang, X., Harris, P. C., & Torres, V. E. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.39 · Cited by 150
Self-citationTran, T., Song, C. J., Nguyen, T. T. T., Cheng, S.-Y., McMahon, J. A., Yang, R., Guo, Q., Dér, B., Lindström, N. O., Lin, D. C.-H., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.005 · Cited by 144
Lakhia, R., Yheskel, M., Flaten, A., Quittner-Strom, E. B., Holland, W. L., & Patel, V. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00352.2017 · Cited by 140
“duct cyst and liver inflammation and fibrosis(10).”
BackgroundIdentification of Biomarkers for PKD1 Using Urinary Exosomes
Hogan, M. C., Bakeberg, J. L., Gainullin, V. G., Irazabal, M. V., Harmon, A. J., Lieske, J. C., Charlesworth, M. C., Johnson, K. L., Madden, B. J., Zenka, R. M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040354 · Cited by 138
Self-citationPolycystin-1 maturation requires polycystin-2 in a dose-dependent manner
Gainullin, V. G., Hopp, K., Ward, C. J., Hommerding, C. J., & Harris, P. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76972 · Cited by 135
Self-citationCiliary Mechanisms of Cyst Formation in Polycystic Kidney Disease
Ma, M., Gallagher, A.-R., & Somlo, S. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028209 · Cited by 133
Polycystin-1: A master regulator of intersecting cystic pathways
Fedeles, S. V., Gallagher, A.-R., & Somlo, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.004 · Cited by 130
Renal plasticity revealed through reversal of polycystic kidney disease in mice
Dong, K., Zhang, C., Tian, X., Coman, D., Hyder, F., Ma, M., & Somlo, S. (2021) · Nature Genetics · doi:10.1038/s41588-021-00946-4 · Cited by 127
Tolvaptan plus Pasireotide Shows Enhanced Efficacy in a PKD1 Model
Hopp, K., Sieben, C. J., Wang, X., Ye, H., Harris, P. C., & Torres, V. E. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013121312 · Cited by 127
Self-citationTranslational research in ADPKD: lessons from animal models
Happé, H., & Peters, D. J. M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.137 · Cited by 116
Ciliary membrane proteins traffic through the Golgi via a Rabep1/GGA1/Arl3-dependent mechanism
Kim, H., Xu, H., Yao, Q., Li, W., Huang, Q., Outeda, P., Cebotaru, V., Chiaravalli, M., Boletta, A., Piontek, K., et al. (2014) · Nature Communications · doi:10.1038/ncomms6482 · Cited by 114
“PC1 is generally far less abundant than PC2 in kidneys and is the central determinant of cyst formation in polycystic kidney and liver diseases 53, 54 .”
Kipp, K. R., Rezaei, M., Lin, L. M., Dewey, E. C., & Weimbs, T. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00551.2015 · Cited by 114
Genetics and Pathogenesis of Autosomal Dominant Polycystic Kidney Disease: 20 Years On
Gall, É. C.-L., Audrézet, M., Meur, Y. L., Chen, J., & Férec, C. (2014) · Human Mutation · doi:10.1002/humu.22708 · Cited by 105
Genetics of Chronic Kidney Disease
Vivante, A. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2308577 · Cited by 104
Downregulating Hedgehog Signaling Reduces Renal Cystogenic Potential of Mouse Models
Tran, P. V., Talbott, G. C., Turbé-Doan, A., Jacobs, D. T., Schonfeld, M. P., Silva, L. M., Chatterjee, A., Prysak, M., Allard, B. A., & Beier, D. R. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013070735 · Cited by 102
A methionine-Mettl3-N-methyladenosine axis promotes polycystic kidney disease
Ramalingam, H., Kashyap, S., Cobo-Stark, P., Flaten, A., Chang, C.-M., Hajarnis, S. S., Hein, K. Z., Lika, J., Warner, G. M., Espíndola‐Netto, J. M., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.024 · Cited by 98
He, K., Ma, X., Xu, T., Li, Y., Hodge, A., Zhang, Q., Torline, J., Huang, Y., Zhao, J., Ling, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05867-1 · Cited by 97
Kidney: polycystic kidney disease
Paul, B. M., & Heuvel, G. B. V. (2014) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.152 · Cited by 94
Audrézet, M., Corbiere, C., Lebbah, S., Morinière, V., Broux, F., Louillet, F., Fischbach, M., Zaloszyc, A., Cloarec, S., Merieau, É., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101051 · Cited by 94
Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease
Devuyst, O., & Torres, V. E. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283621510 · Cited by 90
Self-citationChebib, F. T., Jung, Y., Heyer, C. M., Irazabal, M. V., Hogan, M. C., Harris, P. C., Torres, V. E., & Zoghby, Z. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw008 · Cited by 88
Self-citationLemoine, H., Raud, L., Foulquier, F., Sayer, J. A., Lambert, B., Olinger, E. G., Lefèvre, S., Knebelmann, B., Harris, P. C., Trouvé, P., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.06.013 · Cited by 85
Self-citationGhata, J., & Cowley, B. D. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160018 · Cited by 83
PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression
Lakhia, R., Ramalingam, H., Chang, C.-M., Cobo-Stark, P., Biggers, L. M., Flaten, A., Alvarez, J., Valencia, T., Wallace, D. P., Lee, E. C. Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32543-2 · Cited by 82
Li, S. R., Gulieva, R. E., Helms, L., Cruz, N. M., Vincent, T., Fu, H., Himmelfarb, J., & Freedman, B. (2022) · Nature Communications · doi:10.1038/s41467-022-35537-2 · Cited by 80
Ding, H., Li, L. X., Harris, P. C., Yang, J., & Li, X. (2021) · Nature Communications · doi:10.1038/s41467-021-24799-x · Cited by 79
Self-citationTorrá, R., Furlano, M. M., Ortíz, A., & Ars, E. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab056 · Cited by 78
Cilia and polycystic kidney disease
Ma, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.003 · Cited by 77
CD8+ T cells modulate autosomal dominant polycystic kidney disease progression
Kleczko, E. K., Marsh, K. H., Tyler, L. C., Furgeson, S. B., Bullock, B., Altmann, C. J., Miyazaki, M., Gitomer, B. Y., Harris, P. C., Weiser‐Evans, M. C. M., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.06.025 · Cited by 77
Self-citationIntraflagellar Transport Proteins as Regulators of Primary Cilia Length
Wang, W., Hufft‐Martinez, B. M., Wang, H. H., Kavanaugh, M. A., Maser, R. L., & Tran, P. V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.661350 · Cited by 76
Tulp3 Is a Ciliary Trafficking Gene that Regulates Polycystic Kidney Disease
Legué, E., & Liem, K. F. (2019) · Current Biology · doi:10.1016/j.cub.2019.01.054 · Cited by 74
A novel ADPKD model using kidney organoids derived from disease-specific human iPSCs
Shimizu, T., Mae, S.-I., Araoka, T., Okita, K., Hotta, A., Yamagata, K., & Osafune, K. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.141 · Cited by 73
Durkie, M., Chong, J., Valluru, M. K., Harris, P. C., & Ong, A. C. M. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-01026-4 · Cited by 73
Self-citationPema, M., Drusian, L., Chiaravalli, M., Castelli, M., Yao, Q., Ricciardi, S., Somlo, S., Qian, F., Biffo, S., & Boletta, A. (2016) · Nature Communications · doi:10.1038/ncomms10786 · Cited by 72
Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases
Huang, J. L., Woolf, A. S., Kolatsi‐Joannou, M., Bałuk, P., Sandford, R. N., Peters, D. J. M., McDonald, D. M., Price, K. L., Winyard, P. J. D., & Long, D. A. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090856 · Cited by 71
Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling
Sussman, C. R., Wang, X., Chebib, F. T., & Torres, V. E. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109649 · Cited by 71
Self-citationMolecular Pathways and Therapies in Autosomal-Dominant Polycystic Kidney Disease
Saigusa, T., & Bell, P. D. (2015) · Physiology · doi:10.1152/physiol.00032.2014 · Cited by 68
“functional pkd1 product correlates with disease severity (47).”
BackgroundTrudel, M., Yao, Q., & Qian, F. (2016) · Cells · doi:10.3390/cells5010003 · Cited by 67
“Recent studies have shown that incompletely penetrant PKD1 alleles can impair PC1 cleavage [59].”
BackgroundJafree, D. J., MOULDING, D. A., Kolatsi‐Joannou, M., Perretta‐Tejedor, N., Price, K. L., Milmoe, N. J., Walsh, C., Correra, R. M., Winyard, P. J. D., Harris, P. C., et al. (2019) · eLife · doi:10.7554/elife.48183 · Cited by 66
Self-citationPastor‐Soler, N. M., Li, H., Pham, J., Rivera, D., Ho, P., Mancino, V., Saitta, B., & Hallows, K. R. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00298.2021 · Cited by 65
Arroyo, J., Escobar-Zarate, D., Wells, H. H., Constans, M., Thao, K., Smith, J. M., Sieben, C. J., Martell, M. R., Kline, T. L., Irazabal, M. V., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.01.028 · Cited by 63
Self-citationEffects of hydration in rats and mice with polycystic kidney disease
Hopp, K., Wang, X., Ye, H., Irazabal, M. V., Harris, P. C., & Torres, V. E. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00345.2014 · Cited by 63
“PCK rats (30) and C57BL/6 Pkd1 (10, 11), Pkd2 and 98 Pkd2 (33) mice were maintained in the Animal Facilities of the Department of 99 Veterinary Medicine of the Mayo Clinic, Rochester, MN.”
MethodSelf-citationInterstitial microRNA miR-214 attenuates inflammation and polycystic kidney disease progression
Lakhia, R., Yheskel, M., Flaten, A., Ramalingam, H., Aboudehen, K., Ferrè, S., Biggers, L. M., Mishra, A., Chaney, C. P., Wallace, D. P., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133785 · Cited by 63
“To address this question, we deleted miR-214 in Pkd1RC/RC mice (25).”
BackgroundVasopressin Receptor Antagonists, Heart Failure, and Polycystic Kidney Disease
Torres, V. E. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022838 · Cited by 61
Self-citationYao, G., Su, X., Nguyen, V., Roberts, K., Li, X., Takakura, A., Plomann, M., & Zhou, J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt672 · Cited by 60
“To further confirm that Pacsin 2 interacts with full-length PC1 through binding to the coiled-coil domain in PC1-C-tail, we engineered a pathogenic mutation (Q4215P that interrupts the coiled-coil domain (31)) found in human ADPKD patients into full-length PC1 and used GST-Pacsin 2 to pull down either wild-type YFP-ta…”
MethodCordido, A., Cerecedo, L. B., & García-González, M. Á. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00279 · Cited by 60
“Similarly, other studies suggest that incomplete, penetrant alleles can influences disease severity in ADPKD (62).”
BackgroundLi, L. X., Zhou, J. X., Wang, X., Zhang, H., Harris, P. C., Calvet, J. P., & Li, X. (2020) · Science Advances · doi:10.1126/sciadv.abb3154 · Cited by 60
“Although our study suggests that CDK4/6-SMYD2 signaling may be a regulatory system that could be exploited for restoring cilia length in disease, we should point out that in contrast to short cilia that were observed in Pkd1 homozygous cystic renal epithelial cells, renal tubular cilia can paradoxically lengthen in se…”
ResultSelf-citationSweeney, W. E., Frost, P., & Avner, E. D. (2017) · World Journal of Nephrology · doi:10.5527/wjn.v6.i4.188 · Cited by 59
Olson, R. J., Hopp, K., Wells, H. H., Smith, J. M., Furtado, J., Constans, M., Escobar-Zarate, D., Geurts, A. M., Torres, V. E., & Harris, P. C. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019020150 · Cited by 58
Self-citationZhou, X., Fan, L. X., Li, K., Ramchandran, R., Calvet, J. P., & Li, X. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt556 · Cited by 57
“While there are observations to the contrary (34), abnormally long cilia have been seen in the cystic kidneys of a Pkd1 mutant mouse (35).”
BackgroundMonkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease
Tsukiyama, T., KOBAYASHI, K. P., Nakaya, M., Iwatani, C., Seita, Y., Tsuchiya, H., Matsushita, J., Kitajima, K., Kawamoto, I., Nakagawa, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13398-6 · Cited by 57
Hajarnis, S. S., Patel, V., Aboudehen, K., Attanasio, M., Cobo-Stark, P., Pontoglio, M., & Igarashi, P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.670646 · Cited by 56
Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease
Hopp, K., Catenacci, V. A., Dwivedi, N., Kline, T. L., Wang, W., You, Z., Nguyen, D. T., Bing, K., Poudyal, B., Johnson, G. C., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103697 · Cited by 55
Self-citationPhysiologic mechanisms underlying polycystic kidney disease
Boletta, A., & Caplan, M. J. (2025) · Physiological Reviews · doi:10.1152/physrev.00018.2024 · Cited by 55
Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease
Lee, S. H., & Somlo, S. (2014) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.05.002 · Cited by 55
“A recent study demonstrating that the decrease in the steady-state levels of PC1 that can be partially rescued in a temperature-sensitive manner also points to the importance of PC1 dosage in the modulation of cyst burden [43].”
BackgroundThe fate of the primary cilium during myofibroblast transition
Rozycki, M., Lodyga, M., Lam, J., Miranda, M. Z., Fátyol, K., Speight, P., & Kapùs, A. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-07-0429 · Cited by 55
“Considering only potential direct links, E-cadherin has been reported to associate with polycystin-1 at the cell junctions (Huan and van Adelsberg, 1999), and the level of WT polycystin-1 was proposed to regulate cilium length in a dose-dependent manner (Hopp et al., 2012).”
BackgroundPolycystic kidney disease: novel insights into polycystin function
Luo, L., Roy, S., Li, L., & Ma, M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.01.005 · Cited by 53
Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families
Paul, B. M., Consugar, M. B., Lee, M. R., Sundsbak, J. L., Heyer, C. M., Rossetti, S., Kubly, V. J., Hopp, K., Torres, V. E., Coto, E., et al. (2013) · Kidney International · doi:10.1038/ki.2013.227 · Cited by 53
“Western blotting and quantification for the cleavage assay was performed as described previously (35).”
MethodResultSelf-citationRodríguez, D., Kapoor, S., Edenhofer, I., Segerer, S., Riwanto, M., Kipar, A., Yang, M., Mei, C., & Wuthrich, R. P. (2015) · Kidney & Blood Pressure Research · doi:10.1159/000368540 · Cited by 53
Kim, D. Y., & Park, J. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-2041-4_2 · Cited by 53
Silva, L. M., Jacobs, D. T., Allard, B. A., Fields, T. A., Sharma, M., Wallace, D. P., & Tran, P. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-23341-2 · Cited by 53
Huang, C., Lowerison, M. R., Lucien, F., Gong, P., Wang, D., Song, P., & Chen, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41373-0 · Cited by 53
Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease
Radadiya, P. S., Thornton, M. M., Puri, R. V., Yerrathota, S., Phan, J. D., Magenheimer, B. S., Subramaniam, D., Tran, P. V., Zhu, H., Bolisetty, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141299 · Cited by 53
“Pkd1 Pkd2+/– (PKD) mice were generated by breeding Pkd1RC/RC mice with Pkd2+/– mice (both in C57BL/6J background) provided by Peter Harris (Department of Biochemistry and Molecular Biology, Mayo Graduate School of Biomedical Sciences, Rochester, Minnesota, USA) and Steven Somlo (Section of Nephrology, Department of In…”
Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease
Tao, S., Kakade, V. R., Woodgett, J. R., Pandey, P., Suderman, E. D., Rajagopal, M., & Rao, R. (2015) · Kidney International · doi:10.1038/ki.2014.427 · Cited by 53
“Proliferation of the cystic epithelium is critical for the development and enlargement of renal cysts 25, 54, 55 and progressive cyst enlargement in both ADPKD and ARPKD involve increased proliferation of cyst-lining epithelial cells 36 .”
Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context
Leonhard, W. N., Happe, H., & Peters, D. J. M. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040425 · Cited by 52
Mise, A. D., Tamma, G., Ranieri, M., Centrone, M., van den Heuvel, L. P., Mekahli, D., Levtchenko, E. N., & Valenti, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-23732-5 · Cited by 52
Yheskel, M., Lakhia, R., Cobo-Stark, P., Flaten, A., & Patel, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-38566-y · Cited by 51
Pinto, C. S., Raman, A., Reif, G. A., Magenheimer, B. S., White, C., Calvet, J. P., & Wallace, D. P. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010047 · Cited by 50
Regulation of polycystin expression, maturation and trafficking
Hu, J., & Harris, P. C. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109630 · Cited by 50
Self-citationInsights Into the Molecular Mechanisms of Polycystic Kidney Diseases
Vasileva, V. Y., Sultanova, R. F., Sudarikova, A. V., & Ilatovskaya, D. V. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.693130 · Cited by 50
The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease
Jamadar, A., Suma, S. M., Mathew, S., Fields, T. A., Wallace, D. P., Calvet, J. P., & Rao, R. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04248-9 · Cited by 50
Vishy, C. E., Thomas, C. J., Vincent, T., Crawford, D. K., Goddeeris, M. M., & Freedman, B. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.03.005 · Cited by 49
The Future of Polycystic Kidney Disease Research—As Seen By the 12 Kaplan Awardees
Antignac, C., Calvet, J. P., Germino, G. G., Grantham, J. J., Guay‐Woodford, L. M., Harris, P. C., Hildebrandt, F., Peters, D. J. M., Somlo, S., Torres, V. E., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121192 · Cited by 49
“This is supported by the following findings: (1) cyst enlargement compresses the interstitial matrix and surrounding tubules entraining, distorting, and destroying arterioles, venules, capillaries, and lymphatics; (2) most cysts separate from the tubules from which they formed; (3) an isolated collecting duct cyst can…”
ResultSelf-citationSu, X., Wu, M., Yao, G., El-Jouni, W., Luo, C. T., Tabari, A., & Zhou, J. (2015) · Journal of Cell Science · doi:10.1242/jcs.160556 · Cited by 49
“PC1-R3269C corresponds to a human hypomorphic mutation (PC1R3277C) that gives rise to polycystic kidney disease (Hopp et al., 2012) whereas PC1-M3083R represents an ENUmouse mutant that has a severe cystic phenotype (Herron et al., 2002).”
BackgroundInoue, Y., Sohara, E., Kobayashi, K., Chiga, M., Rai, T., Ishibashi, K., Horie, S., Su, X., Zhou, J., Sasaki, S., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060614 · Cited by 48
Cardiovascular Manifestations and Management in ADPKD
Sagar, P. S., & Rangan, G. K. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.07.017 · Cited by 47
“107 PC-2 localizes to the sarcoplasmic reticulum and loss of PC-2 in murine cardiomyocytes leads to reduced cardiac shortening and cardiac dyssynchrony.”
BackgroundThe Genetics of Vascular Complications in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Rossetti, S., & Harris, P. C. (2013) · Current Hypertension Reviews · doi:10.2174/1573402111309010007 · Cited by 46
“Meanwhile, in the Pkd1nl/nl hypomorphic mouse model that expresses PC-1 at 26% of the normal level in the aorta, dissecting aortic aneurysms are common [38].”
BackgroundInfluentialSelf-citationA mutation affecting polycystin-1 mediated heterotrimeric G-protein signaling causes PKD
Parnell, S. C., Magenheimer, B. S., Maser, R. L., Pavlov, T. S., Havens, M. A., Hastings, M. L., Jackson, S. F., Ward, C. J., Peterson, K. R., Staruschenko, A., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy223 · Cited by 46
“Pkd1 mice have obvious renal defects by 3 months of age, but can survive up to a year of age (23).”
BackgroundSelf-citationChen, W., Perritt, A. F., Morissette, R., Dreiling, J. L., Bohn, M.-F., Mallappa, A., Xu, Z., Quezado, M., & Merke, D. P. (2016) · Human Mutation · doi:10.1002/humu.23028 · Cited by 45
“Similarly, biallelic variants of well-established autosomaldominant disorders resulting in a more severe phenotype have been described in polycystic kidney disease [Sandford, 2009; Bergmann et al., 2011; Hopp et al., 2012], familial hypercholesterolemia [Varret et al.”
BackgroundPolycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling
Streets, A. J., Prosseda, P. P., & Ong, A. C. M. (2020) · JCI Insight · doi:10.1172/jci.insight.135385 · Cited by 45
“liver) (49), inflammation (55), recovery from injury (56), senescence (57), mechanical forces (flow, stretch), or physical constraints (cell shape in 3D tis-”
Background
Metadata
- Authors
- Hopp, K., Ward, C. J., Hommerding, C. J., Nasr, S. H., Tuan, H.-F., Gainullin, V. G., Rossetti, S., Torres, V. E., & Harris, P. C.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Harris, Peter C.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-15
- Volume
- 122
- Issue
- 11
- Pages
- 4257-4273
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3484456
- OpenAlex
- W2085346322
- Cited by
- 442
- References
- 112
- Citations by year
- 2026: 34 · 2025: 34 · 2024: 45 · 2023: 43 · 2022: 44 · 2021: 44 · 2020: 38 · 2019: 23 · 2018: 19 · 2017: 20 · 2016: 21 · 2015: 31 · 2014: 26 · 2013: 18
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic (DK090728)
- American Heart Association
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-058816, DK090728, R01DK044863, P30DK090728, R01DK058816)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Keywords
- autosomal dominant polycystic kidney disease, polycystin-1, PKD1, hypomorphic allele, dosage dependence, disease severity, cyst formation, knockin mouse model, primary cilia, collecting duct, temperature-sensitive mutants, phenotypic variability
- MeSH terms
- Animals, Disease Models, Animal, Severity of Illness Index, Polycystic Kidney, Autosomal Dominant, Protein Folding, Amino Acid Substitution, Mutation, Missense, Animals, Genetically Modified, TRPP Cation Channels, Mice, Gene Knock-In Techniques, Genetic Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.